Procurement teams comparing bronchoscopy platforms face a central problem: head-to-head trials are scarce, while the strongest comparative signals come from studies that differ in endpoints, operators, and imaging workflows. Two 2025–2026 publications supply useful but non-overlapping evidence. RELIANT randomized robotic-assisted bronchoscopy against electromagnetic navigational bronchoscopy using lesional tissue as the outcome [2]. The Vital study compared LungVision and Galaxy robotic bronchoscopy in a community hospital using strict diagnostic yield [1]. Both comparisons raise the same question: whether platform type or tool-to-lesion confirmation drives performance [1]. Any defensible evaluation must therefore separate the navigation system from the imaging that verifies a biopsy location, then measure cost under site-specific procedure volumes [3]. This article outlines those decision points without declaring a universal winner.

Comparative yield depends on which endpoint is reported

The RELIANT trial reported that lesional tissue was obtained in 77.8% of robotic-assisted procedures and 75.5% of electromagnetic procedures, with noninferiority met at a P value of 0.007 among 411 modified intention-to-treat patients [2]. That endpoint tests whether a sample was collected, not whether the final diagnosis was correct. Procurement teams should not treat this 2.3 percentage-point difference as evidence that one navigation technology is clinically superior. The trial was designed as a noninferiority comparison, and the authors stated that comparative effectiveness data were lacking before this study [2].

The Vital study used strict diagnostic yield at index bronchoscopy, defined by ATS/ACCP criteria, and reported 87.6% for Galaxy robotic bronchoscopy versus 74.7% for LungVision, an odds ratio of 2.40 with a 95% confidence interval of 1.10 to 5.24 [1]. Diagnostic accuracy at 1.5 years was 97.1% versus 92% [1]. Even within that cohort, the authors concluded that successful alignment and real-time imaging, not platform type alone, drove results [1]. Different endpoints therefore produce different rankings, and no source here supports an endpoint-agnostic comparison across all four available platforms.

The platform specification that matters is often the imaging integration

Platform descriptions in the reviewed state-of-the-art article show materially different physical and imaging constraints. The Monarch system has a sheath outer diameter of 6 mm, a 4.0 mm bronchoscope, a 2.1 mm working channel, electromagnetic navigation, continuous vision during biopsy, and no listed imaging integration in the comparison table [4]. The Ion system has a single 3.5 mm scope with a 2.0 mm channel, shape-sensing navigation, and vision during navigation but not during biopsy maneuvers because the vision probe must be removed to pass tools [4]. The Galaxy system has a 4.0 mm scope, a 2.1 mm channel, electromagnetic navigation, continuous biopsy vision, and digital tomosynthesis with augmented fluoroscopy via Tool-in-Lesion Tomosynthesis [4].

Johnson & Johnson MedTech states the MONARCH Platform can integrate with GE HealthCare OEC 3D and Siemens Cios Spin imaging systems for tool-in-lesion confirmation [8]. The Vital study found that, within the Galaxy cohort, augmented fluoroscopy localization had an odds ratio of 10.76 for diagnostic success, visual tool adjustment had 9.57, and a tool-in-lesion or tool-to-lesion relationship versus no tool-to-lesion had 16.55, while breath-hold was not associated with improved yield [1]. Because these verification factors are so strongly associated with success, procurement should treat imaging integration as a primary technical decision point rather than a secondary accessory.

Sample scoring: Yield, imaging integration, and volume-matched cost

A hypothetical scoring rubric can be built from the documented data points. Award a maximum of 30 points for evidence quality: 15 only if the vendor can supply strict ATS/ACCP yield data from its own cohort, and 15 if the claimed rate falls within a published range rather than an outlier [7]. Award 30 points for imaging integration: 10 for continuous vision during biopsy, 10 for augmented fluoroscopy or cone beam CT compatibility, and 10 for documented tool-in-lesion or tool-to-lesion confirmation [1,4,8]. Award 40 points for economics: 20 for a cost model that includes capital, repair, and reprocessing, and 20 for a volume-matching analysis against the 756-procedure break-even point [3]. This is a scoring suggestion, not a tested procurement instrument, and each site should re-weight the categories for its own case mix.

Reusable versus single-use economics depends on local volume

A cost-consequence analysis of the Ambu aScope 5 Broncho compared with reusable flexible bronchoscopes at three high-procedure-volume US university hospitals found that reusable bronchoscopes were cost minimizing, with cost savings in 88% of probabilistic sensitivity iterations [3]. The same analysis identified a break-even point of 756 procedures per year or 46 procedures per bronchoscope [3]. Those numbers come from 2022 US dollars, a 3% capital discount over five to eight years, and a micro-costing approach that included capital, repair, and reprocessing costs [3].

A lower-volume site below 756 annual procedures would likely reach a different cost result, but the source does not provide that lower-volume endpoint directly; it reports only that univariate analyses showed sensitivity to procedure volume [3]. Procurement teams should request site-specific volume inputs before applying the break-even figure. The study also examined cross-infection risk, drawing on literature from 2010 to 2020, but the retrieved anchors do not report the numerical infection risk result [3]. Treat the economic findings as volume-dependent and the infection comparison as a topic requiring the full study text.

A local evaluation workflow that avoids the head-to-head gap

Because no prospective direct comparison across all marketed robotic platforms exists, procurement teams can design a three-stage internal evaluation. Stage one fixes the endpoint language: use the ATS/ACCP strict yield denominator based on all index procedures, which the European Respiratory Society article describes as the numerator of procedures yielding a specific malignant or specific benign diagnosis over all procedures performed at the index encounter [7]. The same article states that reported robotic-assisted bronchoscopy yield ranges from roughly 60% to 90%, with one meta-analysis at 84.3%, and that not all papers use strict definitions [7].

Stage two audits imaging workflow, not brochure claims. The platform-specific CT protocols differ; Monarch requires a pre-procedural CT with 1 to 1.25 mm slice thickness at 0.8 to 1 mm intervals, while Ion uses proprietary PlanPoint planning software [7]. The source does not list the Galaxy CT protocol in the retrieved anchor. Stage three models consumable and reprocessing cost at the site's actual annual volume, not the break-even cutoff from high-volume centers [3]. This sequence forces vendors to respond to identical performance, imaging, and cost criteria instead of competing marketing claims.